---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-039405"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T11:24:32.643247+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Roivant reports Q1 net loss of $327.8M, VTAMA revenue $16.7M; cash $1.45B

## Summary
- Net loss $327.8M ($0.38/share) vs $353.8M ($0.48) YoY; non-GAAP net loss $211.5M.
- Product revenue $16.7M from VTAMA (26% gross-to-net yield); ~200K prescriptions since launch.
- Cash, equivalents, restricted cash $1.45B at June 30, down from $1.69B at March 31.
- RVT-3101 shows improved efficacy at week 56 in UC Phase 2b; TAHOE Phase 2 in Crohn's initiated.
- IMVT-1402 Phase 1 data expected Sep 2023 (SAD) and Oct/Nov 2023 (MAD); batoclimab MG data H2 2024.

## SEC filing metadata
- accession: 0001140361-23-039405
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036123039405/0001140361-23-039405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036123039405/brhc20057388_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-039405
- JSON: https://secwatch.observer/filing/0001140361-23-039405.json
- Plain text: https://secwatch.observer/filing/0001140361-23-039405.txt

## Key facts
- Earnings Releases
  Roivant Sciences Ltd. reported financial results for the fiscal quarter ended June 30, 2023.
  - Period: the fiscal quarter ended June 30, 2023
  - Result: reported results
  source text: On August 14, 2023, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000114036123039405/0001140361-23-039405-index.htm
- Earnings Releases
  Roivant Sciences Ltd. reported the first quarter ended June 30, 2023 results: revenue $16.7M.
  - Period: the first quarter ended June 30, 2023
  - Revenue: $16.7M
  - Result: reported results
  source text: trial of IMVT-1402 remains on track for September 2023 (single-ascending dose) and October / November 2023 (multiple-ascending dose) • VTAMA® (tapinarof) net product revenue was $16.7M for the quarter ended June 30, 2023, with nearly 200,000 prescriptions written by approximately 11,500 unique prescribers since launch • VTAMA® gross-to-net yield was 26% for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000114036123039405/0001140361-23-039405-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.